Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $43,764 - $48,935
-756 Reduced 0.55%
136,917 $7.95 Million
Q2 2023

Aug 09, 2023

BUY
$63.71 - $70.74 $698,070 - $775,098
10,957 Added 8.65%
137,673 $8.8 Million
Q1 2023

May 08, 2023

BUY
$65.71 - $74.53 $367,516 - $416,846
5,593 Added 4.62%
126,716 $8.78 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $15,065 - $17,839
-220 Reduced 0.18%
121,123 $8.71 Million
Q3 2022

Nov 07, 2022

SELL
$0.13 - $76.84 $287 - $169,893
-2,211 Reduced 1.79%
121,343 $8.63 Million
Q2 2022

Aug 10, 2022

SELL
$72.62 - $79.98 $201,375 - $221,784
-2,773 Reduced 2.2%
123,554 $9.51 Million
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $106,298 - $127,461
1,729 Added 1.39%
126,327 $9.23 Million
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $70,791 - $82,526
1,320 Added 1.07%
124,598 $7.79 Million
Q3 2021

Nov 10, 2021

SELL
$59.17 - $69.31 $79,642 - $93,291
-1,346 Reduced 1.08%
123,278 $7.29 Million
Q2 2021

Aug 11, 2021

BUY
$61.91 - $67.42 $24,454 - $26,630
395 Added 0.32%
124,624 $8.33 Million
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $7.05 Million - $7.93 Million
118,796 Added 2186.56%
124,229 $7.82 Million
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $6.92 Million - $7.84 Million
-119,892 Reduced 95.66%
5,433 $336,000
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $142,541 - $157,954
-2,482 Reduced 1.94%
125,325 $7.51 Million
Q2 2020

Aug 12, 2020

BUY
$54.82 - $64.09 $53,449 - $62,487
975 Added 0.77%
127,807 $7.39 Million
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $1.64 Million - $2.38 Million
35,268 Added 38.52%
126,832 $7.07 Million
Q4 2019

Feb 07, 2020

BUY
$49.21 - $64.19 $4.51 Million - $5.88 Million
91,564 New
91,564 $5.88 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Eagle Asset Management Inc Portfolio

Follow Eagle Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.